Given the chatter that this is a gold-standard ingredient for hair growth, you may be super tempted to hit "add to cart" on the first product you see if you've noticed changes to your hair such as ...

With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...

Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the presentation of ...

Enzymes are large biological molecules—usually proteins—that speed up chemical reactions. Molecules that speed up chemical ...

The National PKU Alliance (NPKUA), in collaboration with a coalition of PKU-related patient advocacy organizations, announces the TruePKU initiative, a groundbreaking effort to highlight the lived ...

Newborn screening is a critical public health initiative designed to identify genetic and congenital conditions that can be effectively managed if detected early, the Newborn Screening ...

Although similar to those published by the ACMG in 2014, European guidelines for managing PAH deficiency in 2017 stratified ...

The American College of Medical Genetics and Genomics has just published its highly anticipated Evidence-Based Clinical ...

Maze Therapeutics secures $115 million in Series D funding to advance treatments for kidney and metabolic diseases with ...

The Health Insurance Corp. (PhilHealth) will expand its healthcare packages before the end of the year to cover rare diseases ...

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 ...